On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical (SHE: 300558) and its controlling subsidiary Xcovery Holdings, Inc.’s ensartinib (Ensacove), a treatment for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. This marks a significant expansion in the treatment options for patients with this specific type of lung cancer.
eXALT3 Trial Outcomes Support Ensartinib’s Efficacy
The efficacy of ensartinib was assessed in the eXALT3 (NCT02767804) trial, an open-label, randomized, active-controlled, multicenter study involving 290 patients with locally advanced or metastatic ALK-positive NSCLC who had not previously received an ALK-targeted therapy. The trial demonstrated that ensartinib showed a statistically significant improvement in progression-free survival (PFS) when compared to crizotinib, highlighting its potential as an effective treatment option.
Implications for NSCLC Treatment Landscape
The FDA’s approval of ensartinib provides a new therapeutic alternative for patients with ALK-positive NSCLC, particularly for those who have not been previously treated with an ALK-inhibitor. This development is expected to enhance treatment outcomes and offer patients more choices in managing their lung cancer.-Fineline Info & Tech
